U.S. markets closed
  • S&P 500

    3,963.51
    +29.59 (+0.75%)
     
  • Dow 30

    33,781.48
    +183.56 (+0.55%)
     
  • Nasdaq

    11,082.00
    +123.45 (+1.13%)
     
  • Russell 2000

    1,818.29
    +11.39 (+0.63%)
     
  • Crude Oil

    71.79
    -0.22 (-0.31%)
     
  • Gold

    1,801.30
    +3.30 (+0.18%)
     
  • Silver

    23.27
    +0.35 (+1.54%)
     
  • EUR/USD

    1.0563
    +0.0049 (+0.46%)
     
  • 10-Yr Bond

    3.4910
    +0.0830 (+2.44%)
     
  • GBP/USD

    1.2232
    +0.0027 (+0.22%)
     
  • USD/JPY

    136.6440
    +0.1200 (+0.09%)
     
  • BTC-USD

    17,207.74
    +381.24 (+2.27%)
     
  • CMC Crypto 200

    405.01
    +10.32 (+2.62%)
     
  • FTSE 100

    7,472.17
    -17.02 (-0.23%)
     
  • Nikkei 225

    27,574.43
    -111.97 (-0.40%)
     

Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc.

WAYNE, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, CEO of Aclaris, will virtually present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference, which will be available on-demand beginning on Monday, September 12, 2022 at 7:00 a.m. ET. Management will be available September 12th throughout the day for virtual 1x1 meetings.

A webcast of the presentation may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.

Aclaris Contact

investors@aclaristx.com